首页 精密科学(usEXAS)-基本信息

精密科学(usEXAS)-基本信息

日报更新时间:04-15 10:22

周报更新时间:04-11 03:39

行情信息

今开价:131.04

最高价:131.04

成交量:760363.0

昨收价:130.52

最低价:127.215

最新价:130.04

行情图标
概要信息

中文名称:精密科学


英文名称:Exact Sciences


行业:医疗


简介:Exact Sciences Corporation是一家分子诊断公司,专注大肠癌的早期检测和预防


电话:1-608-2845700


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Exact Sciences Corporation是一家分子诊断公司,专注于开发非侵入性的大肠癌筛检产品。精密科学公司开发的Cologuard,是一种非侵入性,基于粪便DNA的大肠癌筛检,用于检测癌症前的病变或息肉,与大肠癌的四个阶段。Cologuard检测涵盖:每天从结肠排出的粪便所剥落之细胞,分离与研究人类DNA之专属与专利方法;以及蛋白质标志物检测粪便中之血液,此为一项利用抗体为基础的免疫化学粪便检测。精密科学公司以粪便为基础的DNA大肠癌筛检查技术,亦聚焦于发炎性肠道疾病(IBD)。此外,精密科学公司与Genzyme Corporation(原NASDAQ:GENZ)签订共同研究、授权及采购协议,以及与MAYO Foundation(梅约基金)为医学教育与研究开发测试,以检测其他胃癌、主要的食道及胰脏癌等。

交易日期 交易人 职位 类型 交易份额 价格
2019-04-02 Stenhouse (Mark) Officer Sell 11192 92.54
2019-04-01 Stenhouse (Mark) Officer Buy 25000 --
2019-03-10 Conroy (Kevin T) Chief Executive Officer Sell 11227 87.21
2019-03-10 Coward (David Scott) Officer Sell 2774 87.21
2019-03-08 Conroy (Kevin T) Chief Executive Officer Buy 24400 --
2019-03-08 Coward (David Scott) Officer Buy 6025 --
2019-03-03 Sebelius (Kathleen) Director Buy 4219 --
2019-02-27 Wyzga (Michael S) Director Sell 500 96.00
2019-02-27 Zanotti (Katherine S) Director Sell 4300 92.33
2019-02-27 Zanotti (Katherine S) Director Sell 509 96.18
2019-02-27 Zanotti (Katherine S) Director Sell 6102 93.45
2019-02-27 Zanotti (Katherine S) Director Sell 7828 91.08
2019-02-27 Zanotti (Katherine S) Director Sell 5461 94.31
2019-02-27 Carey Thomas D Director Sell 7500 96.00
2019-02-27 Johnson (Scott C) Officer Sell 1166 93.20
2019-02-27 Zanotti (Katherine S) Director Sell 800 95.09
2019-02-27 Elliott (Jeffrey Thomas) Chief Financial Officer Sell 2447 93.20
2019-02-27 Doyle James Edward Director Sell 2000 96.00
2019-02-27 Conroy (Kevin T) Chief Executive Officer Sell 10014 93.20
2019-02-27 Coward (David Scott) Officer Sell 2447 93.20
2019-02-26 Johnson (Scott C) Officer Buy 3525 --
2019-02-26 Conroy (Kevin T) Chief Executive Officer Sell 9169 95.07
2019-02-26 Coward (David Scott) Officer Sell 9803 95.07
2019-02-26 Coward (David Scott) Officer Buy 5025 --
2019-02-26 Elliott (Jeffrey Thomas) Chief Financial Officer Buy 5025 --

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
State Street Corporation 2301697 1.78% 56630 2.52% 2019-03-31
Fidelity Management and Research Company 3949109 3.06% 402057 11.33% 2019-03-31
FMR Inc 3964109 3.07% 417057 11.76% 2019-03-31
Ameriprise Financial Inc 4289033 3.32% -27156 -0.63% 2019-03-31
BlackRock Fund Advisors 5424432 4.19% 38183 0.71% 2019-07-31
Wellington Management Company LLP 5415545 4.19% -364314 -6.30% 2019-03-31
BlackRock Inc 5677742 4.40% 101718 1.82% 2019-03-31
T. Rowe Price Associates, Inc. 8293176 6.42% -1565146 -15.88% 2019-03-31
Vanguard Group Inc 11212601 8.68% 418085 3.87% 2019-03-31
J.P. Morgan Investment Management, Inc. 3790466 2.93% 744554 24.44% 2019-07-31
Vanguard Investments Australia Ltd 3609234 2.79% 85889 2.44% 2019-07-31
Viking Global Investors LP 3214982 2.49% -745029 -18.81% 2019-03-31
Columbia Mgmt Investment Advisers, LLC 3042915 2.36% -203050 -6.26% 2019-03-31
PRIMECAP Management Company 2989200 2.31% -205902 -6.44% 2019-03-31
Fidelity Management & Research Company 2811078 2.17% -228670 -7.52% 2019-07-31
Invesco Ltd (OFI / OppenheimerFunds) 2611206 2.02% -1608445 -38.12% 2019-07-31
OppenheimerFunds Inc 2500206 1.94% -365027 -12.74% 2019-03-31
D. E. Shaw & Co LP 2496750 1.93% 693159 38.43% 2019-03-31
Hartford Funds Management Company, LLC 2453103 1.89% -147080 -5.66% 2019-07-31
Winslow Capital Management, LLC 2324941 1.80% 2324941 -- 2019-03-31
Geode Capital Management, LLC 2395680 1.86% 1266968 112.25% 2018-12-31
Zevenbergen Capital Investments LLC 2155357 1.67% -97690 -4.34% 2018-12-31
AllianceBernstein L.P. 2266798 1.76% -11425 -0.50% 2018-12-31
OFI Global Asset Management, Inc. 2500000 1.94% -1630802 -39.48% 2019-04-30
JPMorgan Chase & Co 3395937 2.70% 537266 18.79% 2018-09-30
William Blair Investment Management, LLC 2334045 1.90% 520579 28.71% 2018-09-30
Artisan Partners Limited Partnership 2078909 1.69% 199384 10.61% 2018-09-30
BlackRock Institutional Trust Company NA 3280149 2.67% -24892 -0.75% 2018-06-30
Gilder Gagnon Howe & CO LLC 1948980 1.59% -21009 -1.07% 2018-09-30
Victory Capital Management Inc. 1194939 0.97% -527571 -30.63% 2018-06-30
State Street Corp 2532472 2.07% -1202252 -32.19% 2018-06-30
AllianceBernstein LP 2485482 2.03% -346581 -12.24% 2018-06-30
J.P. Morgan Investment Management Inc 1898398 1.55% 295833 18.46% 2018-06-30
AEGON Scottish Equitable 1557106 1.27% 13786 0.89% 2018-07-31
Fred Alger Management Inc 1350646 1.10% -1494242 -52.52% 2018-06-30
Goldman, Sachs & Co. 1291570 1.05% 171719 15.33% 2018-06-30
Eagle Asset Management, Inc. 1774550 1.46% -18777 -1.05% 2018-03-31
Lord, Abbett & Co LLC 1173304 0.96% 888841 312.46% 2018-06-30
Frontier Capital Management CO Inc 1151667 0.94% 30376 2.71% 2018-06-30
Wasatch Advisors Inc. 1099066 0.90% -50418 -4.39% 2018-06-30
Northern Trust Investments N A 1479551 1.21% 995 0.07% 2018-03-31
Lone Pine Capital LLC 1298001 1.07% 1298001 -- 2018-03-31
NORGES BANK 1143429 0.95% -534243 -31.84% 2017-12-31
Citigroup Inc 2087444 1.73% 891260 74.51% 2017-12-31
Morgan Stanley & Co Inc 1423372 1.18% 288974 25.47% 2017-12-31
Capital World Investors 1750000 1.45% -- -- 2017-12-31
ING Investment Management LLC 2133361 1.78% -56792 -2.59% 2017-09-30
Arrowpoint Asset Management, LLC 1958590 1.64% -380918 -16.28% 2017-09-30
D. E. Shaw & Co., Inc. 5410456 4.99% 57526 1.07% 2016-11-01
UBS Asset Mgmt Americas Inc 1941495 1.79% -17458 -0.89% 2016-09-30
Granahan Investment Management Inc.. 1901550 1.75% 811710 74.48% 2016-09-30
J P Morgan Asset Management (UK) Ltd 1713195 1.58% -354778 -17.16% 2016-09-30
J&P(CHINA)CAPITAL MANAGEMENT CO LTD 1248199 1.15% -- -- 2016-09-30
BlackRock,Inc. 4644277 4.00% 97065389 -- 1999-11-30
William Blair & Co. 5080804 4.00% 106188804 0.10% 1999-11-30
The Vanguard Group 5190960 4.00% 108491064 0.10% 1999-11-30
FMRLLC 5573034 4.00% 116476411 0.10% 1999-11-30
Capital Research Global Investors 9334353 4.00% 195087978 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Harbor Capital Appreciation Fund 840845 0.65% 840845 -- 2019-06-30
MainStay Large Cap Growth Fund 1445600 1.12% -39500 -2.66% 2019-05-31
PrimeCap Odyssey Aggressive Growth Fund 1534000 1.18% -1118900 -42.18% 2019-06-30
Vanguard Mid-Cap Index Fund 1571166 1.21% 1571166 -- 2019-06-30
Vanguard Small Cap Index 1651247 1.28% -1629535 -49.67% 2019-06-30
Vanguard Extended Market Index Fund 1776279 1.37% 34727 1.99% 2019-06-30
JPMorgan Large Cap Growth Fund 1990400 1.54% 819700 70.02% 2019-06-30
Invesco Oppenheimer Global Opports Fund 2500000 1.93% -- -- 2019-06-30
Vanguard Total Stock Market Index Fund 3560260 2.75% 106886 3.10% 2019-06-30
T. Rowe Price Mid-Cap Growth Fund 1398963 1.08% -101037 -6.74% 2019-06-30
Columbia Select Large Cap Growth Fund 862157 0.67% -- -- 2019-06-30
Columbia Focused Large Cap Growth-UBS 862157 0.67% -108108 -11.14% 2019-06-30
Hartford Growth Opportunities Fund 1162303 0.90% -- -- 2019-06-30
T. Rowe Price Health Sciences Fund 865500 0.67% -17800 -2.02% 2019-06-30
JPMorgan Growth Advantage Fund 881000 0.68% -- -- 2019-06-30
American Funds SMALLCAP World Fund 890000 0.69% -- -- 2019-06-30
T. Rowe Price New Horizons Fund 899173 0.69% -121836 -11.93% 2019-06-30
Vanguard Small Cap Growth Index Fund 945749 0.73% -916049 -49.20% 2019-06-30
Fidelity 981100 0.76% -- -- 2019-06-30
Artisan Mid Cap Fund 844414 0.65% -23255 -2.68% 2019-06-30
First Trust NYSE Arca Biotech Fund 1026866 0.80% -- -- 2019-06-30
JHFunds2 Mid Cap Stock Fund 617385 0.48% -- -- 2019-04-30
Vanguard Mid Cap Growth 632865 0.49% 109450 20.91% 2019-03-31
SPDR 773140 0.60% -- -- 2019-05-31
Vanguard Small Cap Index Fund 3285282 2.54% 22640 0.69% 2019-04-30
Oppenheimer Global Opportunities Fund 2500000 1.94% -- -- 2019-03-31
PGIM Jennison Health Sciences Fund 724059 0.56% -- -- 2019-03-31
Anchor Ser Tr SA Wellington CptlApprecPt 608538 0.48% -7097 -1.15% 2019-02-28
T. Rowe Price QM US Small-Cap Gr Eq Fd 717100 0.57% -183000 -20.33% 2018-12-31
JHFunds 2 Mid Cap Stock Fund 665556 0.53% -5708 -0.85% 2019-01-31
AB Discovery Growth Fund 640912 0.51% -33760 -5.00% 2019-01-31
iShares Russell 2000 Growth ETF 1181953 0.94% 2038 0.17% 2018-06-21
VA CollegeAmerica SMALLCAP Wld Fd 890000 0.71% -- -- 2018-12-31
RI CBF Dir AllianceBern Discovery Gr 674672 0.54% -24960 -3.57% 2018-12-31
First Trust Health Care AlphaDEX 696110 0.57% -4824 -0.69% 2018-12-30
Oppenheimer Main Street Fund 881860 0.72% -322750 -26.79% 2018-09-30
RI CBF AllianceBern Discovery Growth 677602 0.55% 19600 2.98% 2018-09-30
Vanguard Small Cap Growth Index Inv 1751081 1.43% 25951 1.50% 2018-07-31
RI CBF AllianceBern Discovery Gr RA 645550 0.53% -4150 -0.64% 2018-07-31
Eagle Small Cap Growth A 640938 0.52% -620578 -49.19% 2018-06-30
Prudential Jennison Health Sciences A 672737 0.55% -- -- 2018-07-31
Lord Abbett Growth Leaders A 676039 0.55% -12952 -1.88% 2018-07-31
JHFunds2 Mid Cap Stock 1 707755 0.58% -- -- 2018-07-31
PRIMECAP Odyssey Aggressive Growth 3067900 2.50% -- -- 2018-06-30
Vanguard Total Stock Mkt Idx 3061305 2.49% 3220 0.11% 2018-07-31
Oppenheimer Global Opportunities A 2500000 2.04% -- -- 2018-07-31
Vanguard Extended Market Idx Inv 1619927 1.32% -- -- 2018-07-31
Oppenheimer Main Street A 1335680 1.09% -- -- 2018-07-31
Hartford Growth Opportunities A 1129548 0.92% -517519 -31.42% 2018-07-31
T. Rowe Price Health Sciences 1048400 0.86% 1048400 -- 2018-06-30
Artisan Mid Cap Investor 958051 0.78% 163738 20.61% 2018-06-30
VA CollegeAmerica Smcap World 529E 890000 0.73% -- -- 2018-06-30
T. Rowe Price QM US Small-Cap Growth Eq 839500 0.68% 839500 -- 2018-06-30
JPMorgan Growth Advantage A 712400 0.58% 5000 0.71% 2018-07-31
Hartford Capital Appreciation A 883978 0.72% -84339 -8.71% 2018-06-30
Delaware Small Cap Core A 638700 0.52% 13300 2.13% 2018-05-31
Hartford Growth Opportunities HLS IA 570383 0.47% -17597 -2.99% 2018-05-31
iShares Russell 2000 Growth 1181953 1.12% 2038 0.17% 2018-06-21
Alger Spectra A 700591 0.58% 73834 11.78% 2018-02-28
Wasatch Small Cap Growth Investor 538048 0.45% -58158 -9.75% 2017-12-31
Fidelity Spartan 530103 0.44% 7073 1.35% 2018-01-31
RS Small Cap Growth A 458300 0.38% 93760 25.72% 2017-12-31
Anchor Ser Tr Capital Apprec 3 441804 0.37% -5253 -1.18% 2017-11-30
Lord Abbett Developing Growth A 614858 0.51% -76667 -11.09% 2017-11-30
William Blair Small-Mid Cap Gr I 457456 0.38% -31942 -6.53% 2017-11-30
Vanguard Explorer Inv 1552568 1.43% 850026 120.99% 2016-09-30
Buffalo Small Cap 741660 0.68% -160 -0.02% 2016-09-30
Meridian Growth Legacy 720361 0.66% 208069 40.62% 2016-12-31
Vanguard VIF Small Co Gr 454343 0.42% -1349 -0.30% 2016-09-30
William Blair Small-Mid Cap Growth Collective Investment Fund 531350 0.49% 29790 5.94% 2016-12-31
JPMorgan Small Cap Growth A 497127 0.46% -9738 -1.92% 2016-12-31
Broadview Opportunity 484774 0.45% -15732 -3.14% 2016-12-31
American Funds IS® Gbl Sm Cap 2656609 2.80% 390000 17.20% 2015-09-30
Fidelity® Select Biotechnology Portfolio 2258602 2.40% -- -- 2015-09-30
iShares Russell 2000 (AU) 1523837 1.80% -1920 -0.10% 2015-11-19
SPDR® S&P Biotech ETF 1205339 1.40% 7872 0.70% 2015-11-19
Invesco Small Cap Growth Fund 1080420 1.10% -6213 -0.60% 2015-09-30
William Blair Small-Mid Cap Growth 984677 1.00% 89200 10.00% 2015-10-31
Eagle Small Cap Growth Fund 979295 1.00% 979295 -- 2015-09-30
UBS (Lux) EF Biotech (USD) 918018 1.00% 13256 1.50% 2015-07-31
Artisan Small Cap Fund 816141 0.80% 38195 4.90% 2015-09-30
VA CollegeAmerica Small Cap World 6801000 7.10% 196000 3.00% 2015-09-30

Michael S. Wyzga Mr. Michael S. Wyzga is an Independent Non-Executive Director at Mereo BioPharma Group Plc, an Independent Director at LogicBio Therapeutics, Inc., a Chairman at X4 Pharmaceuticals, Inc., an Independent Director at EXACT Sciences Corp., a President at Bioleap, Inc. (Florida) and a Chairman at Gensight Biologics SA. He is on the Board of Directors at Mereo BioPharma Group Plc, LogicBio Therapeutics, Inc., EXACT Sciences Corp., Dohmen Co. and International Institute of New England, Inc. Mr. Wyzga was previously employed as a Chairman by Arsanis, Inc., a Chairman by X4 Pharmaceuticals, Inc. /Old/, a Chief Financial Officer by Kew, Inc., a Member-Supervisory Board by Prosensa Holding NV, an Independent Director by Akebia Therapeutics, Inc., an Independent Director by OncoMed Pharmaceuticals, Inc., an Independent Director by Idenix Pharmaceuticals LLC, a President, Chief Executive Officer & Director by Radius Health, Inc., a Chief Financial Officer by Aura Biosciences, Inc., a Chief Financial Officer & Executive Vice President by Genzyme Corp., a Chief Financial Officer by Sovereign Hill Software, Inc., a Chief Financial Officer & Vice President by CacheLink Corp., a Vice President-Finance by Lotus Development Corp., and a Principal by Digital Equipment Corp. He also served on the board at Altus Pharmaceuticals, Inc. and Boch Centre. He received his undergraduate degree from Suffolk University and an MBA from Providence College.
Graham Peter Lidgard Founder of Matritech, Inc., Graham Peter Lidgard presently is Chief Science Officer, SVP-Research & Development at EXACT Sciences Corp. Dr. Lidgard previously held the position of Senior Vice President-Research & Development at Ngen, Inc., Vice President-Research & Development of Gen-Probe, Inc., Vice President-Product Development at Ciba Corning Diagnostics Corp. and Vice President-Product Development at Matritech, Inc. He received an undergraduate degree and a doctorate from The University of Manchester.
Kevin T. Conroy Kevin T. Conroy holds the position of Chairman, President & Chief Executive Officer of EXACT Sciences Corp. He is also on the board of 7 other companies. In the past he held the position of Partner at McDermott Will & Emery LLP, Director at Bioforward, Inc., Partner at Pattishall, McAuliffe, Newbury, Hilliard & Geraldson LLP, President & Chief Executive Officer of Third Wave Technologies, Inc. and Counsel-Intellectual Property at GE Healthcare Ltd. Mr. Conroy received an undergraduate degree from Michigan State University and a graduate degree from The University of Michigan Law School.
D. Scott Coward D. Scott Coward occupies the position of Secretary, Chief Administrative Officer & SVP at EXACT Sciences Corp. Mr. Coward is also on the board of Wisconsin Technology Council and Member of The North Carolina Bar Association. Mr. Coward previously occupied the position of Partner at Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan LLP, Partner at K&L Gates LLP, Associate General Counsel at GE Medical Systems Information Systems and Secretary & General Counsel at Blue Rhino Corp. D. Scott Coward received an undergraduate degree from the University of North Carolina at Chapel Hill and a graduate degree from Columbia Law School.
Kevin T. Conroy Kevin T. Conroy holds the position of Chairman, President & Chief Executive Officer of EXACT Sciences Corp. He is also on the board of 7 other companies. In the past he held the position of Partner at McDermott Will & Emery LLP, Director at Bioforward, Inc., Partner at Pattishall, McAuliffe, Newbury, Hilliard & Geraldson LLP, President & Chief Executive Officer of Third Wave Technologies, Inc. and Counsel-Intellectual Property at GE Healthcare Ltd. Mr. Conroy received an undergraduate degree from Michigan State University and a graduate degree from The University of Michigan Law School.
Daniel J. Levangie Mr. Daniel J. Levangie is President-Drug Delivery Division at Insulet Corp. He is on the Board of Directors at Dune Medical Devices Ltd., EXACT Sciences Corp., CereVasc LLC and Constitution Medical, Inc. Mr. Levangie was previously employed as an Independent Director by LipoScience, Inc., Chairman by Keystone Dental, Inc., Co-Founder & Managing Partner by Constitution Medical Investors, Inc., Non-Executive Chairman by ev3, Inc., President, Chief Commercial Officer & EVP by CYTYC Surgical Products, President, Chief Executive & Operating Officer by Cytyc Health Corp., Executive Vice President by Cytyc Corp., a Principal by Abbott Laboratories, Managing Partner by Aton Partners LLC, a Trustee by Excel Academy Charter School, and Chairman by HyperMed, Inc. He also served on the board at Hologic, Inc. He received his undergraduate degree from Northeastern University.
Barry M. Berger Currently, Barry M. Berger holds the position of Co-Chief Medical Officer & Head-Medical Affairs at EXACT Sciences Corp. Dr. Berger is also Member-Economics Committee at American College of Medical Genetics & Genomics, Member-Health Policy Task Group at National Colorectal Cancer Roundtable and Member-Executive Committee at Massachusetts Society of Pathologists, Inc. In his past career Dr. Berger held the position of Pathology Director at Harvard Pilgrim Health Care, Inc. Barry M. Berger received an undergraduate degree from Miami University and a doctorate from Perelman School of Medicine.
Daniel J. Levangie Mr. Daniel J. Levangie is President-Drug Delivery Division at Insulet Corp. He is on the Board of Directors at Dune Medical Devices Ltd., EXACT Sciences Corp., CereVasc LLC and Constitution Medical, Inc. Mr. Levangie was previously employed as an Independent Director by LipoScience, Inc., Chairman by Keystone Dental, Inc., Co-Founder & Managing Partner by Constitution Medical Investors, Inc., Non-Executive Chairman by ev3, Inc., President, Chief Commercial Officer & EVP by CYTYC Surgical Products, President, Chief Executive & Operating Officer by Cytyc Health Corp., Executive Vice President by Cytyc Corp., a Principal by Abbott Laboratories, Managing Partner by Aton Partners LLC, a Trustee by Excel Academy Charter School, and Chairman by HyperMed, Inc. He also served on the board at Hologic, Inc. He received his undergraduate degree from Northeastern University.
Daniel J. Levangie Mr. Daniel J. Levangie is President-Drug Delivery Division at Insulet Corp. He is on the Board of Directors at Dune Medical Devices Ltd., EXACT Sciences Corp., CereVasc LLC and Constitution Medical, Inc. Mr. Levangie was previously employed as an Independent Director by LipoScience, Inc., Chairman by Keystone Dental, Inc., Co-Founder & Managing Partner by Constitution Medical Investors, Inc., Non-Executive Chairman by ev3, Inc., President, Chief Commercial Officer & EVP by CYTYC Surgical Products, President, Chief Executive & Operating Officer by Cytyc Health Corp., Executive Vice President by Cytyc Corp., a Principal by Abbott Laboratories, Managing Partner by Aton Partners LLC, a Trustee by Excel Academy Charter School, and Chairman by HyperMed, Inc. He also served on the board at Hologic, Inc. He received his undergraduate degree from Northeastern University.
David P. Harding David P. Harding is Senior Vice President-Business Development of EXACT Sciences Corp. Mr. Harding previously was Principal at McKinsey & Co., Inc., Chief Commercial Officer for T2 Biosystems, Inc., Senior Vice President-Corporate Strategy at Hologic, Inc. President of Cytyc International, Inc. and Senior Vice President at Cytyc Corp. (both are subsidiaries of Hologic, Inc.) and Chief Commercial Officer for OvaScience, Inc. Mr. Harding received an undergraduate degree from the University of Southern California and an MBA from The Wharton School of the University of Pennsylvania.
Vic Parker Mr. Andrew M. Slavitt is a Chairman at Quality Software Services, Inc. and a President at Executive Health Resources, Inc. He is on the Board of Directors at EXACT Sciences Corp., Center for Affordable Quality Health Care, Guthrie Theater Foundation, Jewish Community Action and Somatus, Inc. Mr. Slavitt was previously employed as a Group Executive Vice President by Optum, Inc., an Independent Director by Capella Education Co., a Chief Executive Officer by Ingenix, Inc., a Chief Executive Officer-Consumer Solutions by UnitedHealth Group, Inc., a Chief Executive Officer by HealthAllies, Inc., an Investment Banker by Goldman Sachs & Co. LLC, a Strategy Consultant by McKinsey & Co., Inc., and a Chief Operating Officer by PAULA Financial. He received his undergraduate degree from The Wharton School of the University of Pennsylvania, an undergraduate degree from The College of Arts & Sciences and an MBA from Harvard Business School.
John A. Fallon Founder of North Shore Health System, John A. Fallon is a businessperson who has been at the helm of 5 different companies is Chairman of New England Healthcare Institute and on the board of 6 other companies. In the past he occupied the position of President & Chief Executive Officer for North Shore Health System, Chief Executive Officer of Charter Professional Services Corp., Chief Medical Officer of North Shore Medical Center, Inc., Chairman at Partners HealthCare System, Inc., Chief Executive Officer-Clinical Affairs at State University of New York at Downstate Medical Center, Chief Executive Officer-Clinical Affairs at The State University of New York, Senior Vice President at Blue Cross & Blue Shield of Massachusetts, Inc. and Chairman-Medical Standards at National Committee for Quality Assurance. He received an undergraduate degree from College of the Holy Cross (Massachusetts), an MBA from the University of South Florida and a doctorate from Tufts University School of Medicine.
Katherine S. Napier Katherine S. Napier is on the board of EXACT Sciences Corp., Cutera, Inc., Xavier University and RxDino LLC. Ms. Napier previously held the position of Chairman of Natural Products Group, Inc., VP & GM-North American Pharmaceutical Business at Procter & Gamble Co., Senior Vice President-Marketing for McDonald's Corp. and Chief Executive Officer at Arbonne International LLC. Katherine S. Napier received an MBA from Xavier University and an undergraduate degree from Georgetown University.
Gary Frings Founder of Systems Solutions Group, Inc. and Performanceg2, Inc., Gary Frings currently occupies the position of Chief Information Officer of EXACT Sciences Corp. He is also on the board of Bioforward, Inc. In the past Mr. Frings was Chairman of Northern California Cognos Users Group, President at Performanceg2, Inc., Managing Partner at Senturus, Inc., Principal at Andersen Consulting LLP (GB), President at Systems Solutions Group, Inc. and Executive Vice President for Eclipse Networks, Inc. He received an undergraduate degree from the University of Wisconsin.
Jeffrey T. Elliott Jeffrey T. Elliott is on the board of Exagen, Inc. and Chief Financial Officer of EXACT Sciences Corp. In his past career he occupied the position of Senior Business Analyst at Walgreens Health Services, Inc., Senior Consultant at Cap Gemini Ernst & Young LLC and Senior Research Analyst at Robert W. Baird & Co., Inc. (Broker). Mr. Elliott received an undergraduate degree from the University of Illinois and an MBA from The University of Chicago Booth School of Business.
Jeffrey T. Elliott Jeffrey T. Elliott is on the board of Exagen, Inc. and Chief Financial Officer for EXACT Sciences Corp. In his past career he occupied the position of Senior Business Analyst at Walgreens Health Services, Inc., Senior Consultant at Cap Gemini Ernst & Young LLC and Senior Research Analyst at Robert W. Baird & Co., Inc. (Broker). Mr. Elliott received an undergraduate degree from the University of Illinois and an MBA from The University of Chicago Booth School of Business.
Vic Parker Dr. Pierre Jacquet is on the Board of Directors at EXACT Sciences Corp. Dr. Jacquet was previously employed as an Advisor by Transfer Technologies Commercialisation Capital. He received his MBA from the University of Virginia Darden School of Business and a doctorate degree from the University of Liege.
Eli D. Casdin Mr. Eli D. Casdin is a Chief Investment Officer at Casdin Capital LLC and at Casdin Capital / Private Equity/. He is on the Board of Directors at Casdin Partners Offshore Ltd. He has spent the past 13 years analyzing and investing in disruptive technologies and business models in Life Sciences and Healthcare. Mr. Casdin was previously employed as an Associate by Bear, Stearns & Co., Inc., a Research Analyst by Cooper Hill Partners LLC, and a Vice President by AllianceBernstein LP. He also served on the board at SynapDx Corp. Mr. Casdin holds a B.S. from Columbia University and MBA from Columbia Business School.
Scott C. Johnson Scott C. Johnson is Senior Vice President-Research & Development at EXACT Sciences Corp. In the past he occupied the position of Principal at CHMIERx and Vice President-Product Development & Manufacturing at Luminex Corp. and Vice President-Product Development at EraGen Biosciences, Inc. (a subsidiary of Luminex Corp.). Dr. Johnson received a doctorate from the University of Wisconsin, an undergraduate degree from Rochester Institute of Technology and an MBA from Kellogg School of Management.
James Edward Doyle James Edward Doyle is on the board of EXACT Sciences Corp. and Chairman of The Henry J. Kaiser Family Foundation and Partner at Doyle & Boyce Strategies LLC. In his past career he held the position of Governor at State of Wisconsin, District Attorney at County of Dane (Wisconsin), of Counsel at Foley & Lardner LLP and President at National Association of Attorneys General. James Edward Doyle received an undergraduate degree from the University of Wisconsin and a graduate degree from Harvard Law School.
Thomas D. Carey Founder of Perspective Group LLC, Thomas D. Carey is Managing Partner at this company. Mr. Carey is also on the board of EXACT Sciences Corp. and Catholic Charitable Bureau of the Archdiocese of Boston, Inc. In his past career Mr. Carey occupied the position of Member of Spencer Stuart, Inc. and Partner at Russell Reynolds Associates, Inc. Mr. Carey received an undergraduate degree from College of the Holy Cross (Massachusetts) and a graduate degree from Kellogg School of Management.
Kathleen Sebelius Kathleen Sebelius is the former Governor of State of Kansas (Kansas). Ms. Sebelius is Chief Executive Officer at this company. Ms. Sebelius is also Co-Chairman at The Aspen Institute, Inc. and Member of The Democratic Party (United States) and on the board of 8 other companies. In the past Kathleen Sebelius occupied the position of Senior Advisor at Just Inc, Governor at State of Kansas (Kansas) and Secretary at US Department of Health & Human Services (DC). She received an undergraduate degree from Trinity College (District of Columbia) and a graduate degree from the University of Kansas.
Sarah Condella Currently, Sarah Condella is Senior Vice President-Human Resources for EXACT Sciences Corp. In the past she was Project Director at University of Wisconsin Survey Center and Manager-Human Resources at GE Healthcare, Inc. She received an undergraduate degree and an MBA from the University of Wisconsin.
Sandra Statz Presently, Sandra Statz occupies the position of Vice President-Regulatory, Clinical & Quality at EXACT Sciences Corp. She previously held the position of Director & Associate Director-Clinical Operations at Quintiles, Inc. (California) and Director-Clinical Affairs at Third Wave Technologies, Inc. Ms. Statz received an undergraduate degree and a graduate degree from the University of Wisconsin.
Tim Caprez Presently, Tim Caprez occupies the position of Chief Compliance Counsel & Vice President at EXACT Sciences Corp. Mr. Caprez is also Co-Editor at American Bar Association, Member of State Bar of Wisconsin, Member of Illinois State Bar Association, Member of American Health Lawyers Association and Co-Chair-Health Law Section at Milwaukee Bar Association, Inc. In his past career Mr. Caprez held the position of Attorney at O'Neil, Cannon, Hollman, Dejong & Laing SC, Attorney at Hogan Marren Ltd., Attorney at Whyte Hirschboeck Dudek SC and Senior Counsel & Head-Compliance at GE Healthcare, Inc. Tim Caprez received a graduate degree from Loyola University of Chicago School of Law and an undergraduate degree from the University of Wisconsin.
Gary Frings Founder of Systems Solutions Group, Inc. and Performanceg2, Inc., Gary Frings currently occupies the position of Chief Information Officer of EXACT Sciences Corp. He is also on the board of Bioforward, Inc. In the past Mr. Frings was Chairman of Northern California Cognos Users Group, President at Performanceg2, Inc., Managing Partner at Senturus, Inc., Principal at Andersen Consulting LLP (GB), President at Systems Solutions Group, Inc. and Executive Vice President for Eclipse Networks, Inc. He received an undergraduate degree from the University of Wisconsin.
Paul J. Limburg Currently, Paul J. Limburg occupies the position of Co-Chief Medical Officer at EXACT Sciences Corp. In his past career Dr. Limburg was Medical Director-Global Business Solutions at The Mayo Clinic (Old). He received an undergraduate degree from Augustana College (Illinois), a doctorate from Mayo Medical School and a graduate degree from Johns Hopkins Bloomberg School of Public Health.
Mark Stenhouse Mark Stenhouse is President-Cologuard at EXACT Sciences Corp.
Kyle Stacey Currently, Kyle Stacey holds the position of Controller & Vice President at EXACT Sciences Corp. Mr. Stacey received a graduate degree and an undergraduate degree from The University of Arkansas.
Megan Jones Megan Jones is Associate Manager-Investor Relations at EXACT Sciences Corp.
Ana Hooker Ana Hooker occupies the position of Senior Vice President-Operations for EXACT Sciences Corp. In her past career Ms. Hooker held the position of President of American Society for Clinical Laboratory Science, President for Association for Molecular Pathology and President-Utah chapter at Clinical Laboratory Management Association, Inc. She received an MBA from Westminster College (Pennsylvania) and an undergraduate degree from Kansas State University.
Kristen Weiler Kristen Weiler is Vice President-Marketing of EXACT Sciences Corp. She received an undergraduate degree from the University of Wisconsin-Whitewater.
Vic Parker Currently, Vic Parker occupies the position of Head-Sales at EXACT Sciences Corp. Mr. Parker received an undergraduate degree from Clemson University and an MBA from Emory University.

量化对比

全部评论 1

  • 美股抗癌医药股集体上涨,Merrimack制药涨超8%,Inovio制药盘中一度涨17%,Seagen涨超4%,精密科学涨超2%,Biogen制药涨近2%。

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐